On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


DGE 5th Clinical Trials Agreements Conference To Discuss Transparency Among CTA Shareholders

DGE invites leaders, executives and professionals from the biotech, pharma, and medical device sectors, to attend the 5th Clinical Trials Agreements Conference being held August 21-22, 2024, in Philadelphia. The conference focuses on discussions such as accelerating negotiations, AI advancements, fair market value, and building a modern day clinical site budget.

The event is hosted by Dynamic Global Events (“DGE”), a global leader in organizing B2B events. The global event company caters to the dynamic informational and networking needs of the pharma, biotech, medical devices, and all healthcare industries.

Clinical Trial Agreements rely on effective communication among sponsors, CROs, and the research institution. Key topics that will be covered include enhancing communication transparency, evaluating the impact of CROs on negotiation timelines, and highlighting site forms and institution policies in CTAs.

Featured topics covered include:

  • Apply Key Lessons from Decentralized and Remote Clinical Trials 
  • Evaluate the Impact of CROs on Negotiation Timelines 
  • Fast-Track Your CTA Negotiations: Key Factors and Best practices 
  • Examine the Recent FDA Guidance Surrounding Digital Health Technologies 
  • Revolutionize Contract Review Processes by Harnessing AI to Enhance Operational Efficiency 
  • Map out CTAs in a Global Landscape 
  • Build a Modern – Day Clinical Site Budget: Hybrid Studies, DCT, and Naïve Sites

In addition, attendees can learn the intricacies of CTA negotiations from industry experts through audience Q&A as well as networking breaks. We hope to see you there!

To know more, please visit https://ibn.fm/Bjrxt.

From Our Blog

Annovis Bio Inc. (NYSE: ANVS) Announces New Executive Team Members

July 23, 2024

Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”), is thrilled to welcome four seasoned professionals to its executive team. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, said the company was delighted to have […]

Rotate your device 90° to view site.